Dorsey & Whitney Trust CO LLC trimmed its position in shares of Teleflex Incorporated (NYSE:TFX) by 47.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 585 shares of the medical technology company’s stock after selling 536 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Teleflex were worth $213,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. First Personal Financial Services grew its position in shares of Teleflex by 60.0% in the 2nd quarter. First Personal Financial Services now owns 80 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 30 shares during the period. Winslow Evans & Crocker Inc. boosted its holdings in shares of Teleflex by 46.9% in the second quarter. Winslow Evans & Crocker Inc. now owns 94 shares of the medical technology company’s stock valued at $34,000 after buying an additional 30 shares during the period. Financial Management Professionals Inc. bought a new stake in shares of Teleflex during the second quarter worth $71,000. CSat Investment Advisory L.P. raised its holdings in shares of Teleflex by 32.1% during the first quarter. CSat Investment Advisory L.P. now owns 255 shares of the medical technology company’s stock worth $74,000 after acquiring an additional 62 shares during the period. Finally, Ellevest Inc. lifted its position in Teleflex by 162.1% in the 2nd quarter. Ellevest Inc. now owns 249 shares of the medical technology company’s stock valued at $91,000 after acquiring an additional 154 shares in the last quarter. 91.29% of the stock is owned by institutional investors.
Shares of NYSE TFX opened at $389.39 on Friday. The stock has a 50 day moving average price of $380.30 and a 200 day moving average price of $350.22. Teleflex Incorporated has a 52 week low of $221.27 and a 52 week high of $409.27. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.26 and a current ratio of 3.38. The stock has a market capitalization of $18.45 billion, a PE ratio of 38.33, a price-to-earnings-growth ratio of 2.97 and a beta of 1.00.
Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.68. The company had revenue of $567.00 million for the quarter, compared to analysts’ expectations of $537.85 million. Teleflex had a return on equity of 17.15% and a net margin of 18.99%. The business’s revenue was down 13.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.66 EPS. As a group, research analysts forecast that Teleflex Incorporated will post 10.28 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.35%. The ex-dividend date is Thursday, August 13th. Teleflex’s dividend payout ratio (DPR) is currently 12.20%.
Several analysts have issued reports on TFX shares. Morgan Stanley boosted their price target on Teleflex from $380.00 to $400.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Raymond James reissued a “buy” rating on shares of Teleflex in a research report on Friday, August 28th. Finally, SVB Leerink upped their price target on Teleflex from $400.00 to $425.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $389.40.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $373.74, for a total value of $74,748.00. Following the completion of the sale, the director now owns 1,321 shares in the company, valued at $493,710.54. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.21% of the company’s stock.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Read More: What is Cost of Debt?
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.